search
Back to results

Effect of Endoplasmic Reticulum Stress on Metabolic Function (TUDCA/PBA)

Primary Purpose

Insulin Resistance, Diabetes, Obesity

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
tauroursodeoxycholic acid
placebo
sodium phenylbutyrate
Sponsored by
Washington University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Insulin Resistance focused on measuring obesity, insulin resistance, type II diabetes

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • BMI range 30 to 45
  • sedentary (defined as regular exercise < 1 h per week or < 2 x/week for the last 6 months)

Exclusion Criteria:

  • active or previous infection with hepatitis B or C
  • liver diseases
  • history of alcohol abuse
  • current alcohol consumption > 20 g/day
  • severe hypertriglyceridemia ( > 400 mg/dL)
  • active peptic ulcer disease
  • taking cholestyramine or oral contraceptives
  • women who are pregnant or lactating

Sites / Locations

  • Washington University School of Medicine

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Experimental

Experimental

Arm Label

Placebo

tauroursodeoxycholic acid

PBA

Arm Description

Subjects will be given a placebo rather than tauroursodeoxycholic acid.

Subjects will receive tauroursodeoxycholic acid for four weeks.

Subjects will receive sodium phenylbutyrate for four weeks.

Outcomes

Primary Outcome Measures

Body Composition
Fat mass (%)

Secondary Outcome Measures

Insulin Sensitivity in the Liver
HISI (hepatic insulin sensitivity index). HISI is the inverse of the product of endogenous glucose production and plasma insulin concentration and provides an index of how well circulating insulin controls the amount of glucose supplied by the liver. A higher number is indicative of greater insulin sensitivity.
VLDL-triglyceride (TG) Concentration

Full Information

First Posted
October 10, 2008
Last Updated
April 25, 2018
Sponsor
Washington University School of Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT00771901
Brief Title
Effect of Endoplasmic Reticulum Stress on Metabolic Function
Acronym
TUDCA/PBA
Official Title
Effect of Endoplasmic Reticulum Stress on Metabolic Function
Study Type
Interventional

2. Study Status

Record Verification Date
April 2018
Overall Recruitment Status
Completed
Study Start Date
February 2008 (Actual)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
December 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Washington University School of Medicine

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Normally, the hormone insulin works to help keep blood sugar normal. However, as a person gains weight, insulin does not work as well and blood sugar tends to be a little higher than normal. This is called "insulin resistance". Two investigational drugs (not approved by the Food and Drug Administration) for the treatment of high lipid levels or insulin resistance are being examined in this study: one drug is called tauroursodeoxycholic acid (TUDCA), the other is called sodium phenylbutyrate (PBA). This study is designed to test if TUDCA and/or PBA is effective in people who are obese with insulin resistance and high lipids. We hypothesize that pharmacologically-induced decreases in ER stress will improve insulin action and hepatic lipid metabolism in obese subjects.
Detailed Description
A 4-week randomized, controlled trial will be conducted to evaluate the following specific aims in obese subjects: Determine the effect of treatment with TUDCA or PBA on: Body fat distribution: a) intrahepatic triglyceride (IHTG) content, b) intramyocellular triglyceride (IMTG) content, and c) intra-abdominal fat content, assessed by using magnetic resonance spectroscopy and magnetic resonance imaging. In vivo insulin sensitivity in adipose tissue (suppression of lipolysis), liver (suppression of glucose production), and skeletal muscle (stimulation of glucose uptake), assessed by using the hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotope tracer infusion. VLDL-triglyceride (TG) and VLDL-apolipoprotein-B100 (apoB-100) secretion rates, assessed by stable isotopically labeled tracer infusion methods. Skeletal muscle intracellular insulin signaling, fatty acid oxidation, and markers of inflammation, assessed by evaluating skeletal muscle biopsies ex vivo. Adipose tissue insulin signaling, ER stress, and inflammation, assessed by evaluating adipose tissue biopsies ex vivo.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insulin Resistance, Diabetes, Obesity
Keywords
obesity, insulin resistance, type II diabetes

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
101 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Subjects will be given a placebo rather than tauroursodeoxycholic acid.
Arm Title
tauroursodeoxycholic acid
Arm Type
Experimental
Arm Description
Subjects will receive tauroursodeoxycholic acid for four weeks.
Arm Title
PBA
Arm Type
Experimental
Arm Description
Subjects will receive sodium phenylbutyrate for four weeks.
Intervention Type
Drug
Intervention Name(s)
tauroursodeoxycholic acid
Other Intervention Name(s)
TUDCA
Intervention Description
1750 mg/day for four weeks. Seven pills daily, 2 with breakfast, 2 with lunch, and 3 with dinner.
Intervention Type
Other
Intervention Name(s)
placebo
Intervention Description
7 pills daily for 4 weeks
Intervention Type
Drug
Intervention Name(s)
sodium phenylbutyrate
Other Intervention Name(s)
PBA
Intervention Description
20g/day for four weeks.
Primary Outcome Measure Information:
Title
Body Composition
Description
Fat mass (%)
Time Frame
Baseline and four weeks
Secondary Outcome Measure Information:
Title
Insulin Sensitivity in the Liver
Description
HISI (hepatic insulin sensitivity index). HISI is the inverse of the product of endogenous glucose production and plasma insulin concentration and provides an index of how well circulating insulin controls the amount of glucose supplied by the liver. A higher number is indicative of greater insulin sensitivity.
Time Frame
Baseline and four weeks
Title
VLDL-triglyceride (TG) Concentration
Time Frame
Baseline and four weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: BMI range 30 to 45 sedentary (defined as regular exercise < 1 h per week or < 2 x/week for the last 6 months) Exclusion Criteria: active or previous infection with hepatitis B or C liver diseases history of alcohol abuse current alcohol consumption > 20 g/day severe hypertriglyceridemia ( > 400 mg/dL) active peptic ulcer disease taking cholestyramine or oral contraceptives women who are pregnant or lactating
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Samuel Klein, MD
Organizational Affiliation
Washington University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Washington University School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
20522594
Citation
Kars M, Yang L, Gregor MF, Mohammed BS, Pietka TA, Finck BN, Patterson BW, Horton JD, Mittendorfer B, Hotamisligil GS, Klein S. Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 2010 Aug;59(8):1899-905. doi: 10.2337/db10-0308. Epub 2010 Jun 3.
Results Reference
result

Learn more about this trial

Effect of Endoplasmic Reticulum Stress on Metabolic Function

We'll reach out to this number within 24 hrs